Kura Oncology
KURA
152 hedge funds and large institutions have $1.06B invested in Kura Oncology in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 50 reducing their positions, and 22 closing their positions.
440% more call options, than puts
Call options by funds: $7.27M | Put options by funds: $1.35M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
18% more capital invested
Capital invested by funds: $898M → $1.06B (+$161M)
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
2.52% more ownership
Funds ownership: 96.32% → 98.84% (+2.5%)
6% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 50
1% more funds holding
Funds holding: 151 → 152 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$42.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$16.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$16.5M |
| 4 |
DM
Deerfield Management
New York
|
+$13M |
| 5 |
Holocene Advisors
New York
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$79.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$25.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.1M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.77M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.17M |
KURA Hedge Fund Activity: Q1 2022 in Review
152 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2022, worth a combined $1.06B — up 18% from $898M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KURA positions and 22 closed out — a net gain of 3 holders — while 53 added to existing stakes and 50 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $42.1M. The largest seller was Fidelity Investments, cutting an estimated $79.6M.
- 152 institutional investors held Kura Oncology (KURA) as of Q1 2022, up from 151 in Q4 2021.
- Funds reported $1.06B of Kura Oncology stock for Q1 2022, up 18% quarter-over-quarter.
- 25 funds opened new Kura Oncology positions in Q1 2022 and 22 closed out, a net change of +3 holders.
- The largest Kura Oncology buyer in Q1 2022 was EcoR1 Capital, an estimated $42.1M added.
- The largest Kura Oncology seller in Q1 2022 was Fidelity Investments, an estimated $79.6M sold.
Based on aggregated 13F filings for Q1 2022.